drug

Evenamide

Evenamide 15 mg bidNW-3509aNW-3509A
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Newron Pharmaceuticals SPA
4 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

4
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
NCT07184619Phase 3Recruiting
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
NCT04461119Phase 2Completed
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
NCT02624167Phase 2Completed
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
NCT01955564Phase 1Completed

KOLs & investigators

2
Ravi Anand, MDKOL score 0
Mark Leibowitz, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Newron Pharmaceuticals SPA
company
trial
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
PHASE3
trial
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
PHASE2
trial
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
PHASE2
trial
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
PHASE1
trial
indication
Schizophrenia
indication
Chronic Schizophrenia
indication
Treatment-resistant Schizophrenia
indication
Schizophrenia
indication
KOL
Ravi Anand, MD
KOL score 0
person
Mark Leibowitz, MD
KOL score —
person